Cell Therapeutics (CTIC) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Cell Therapeutics (CTIC)

CTIC 9.090

0.0%

Jun 26 5:00 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: Ian@SI	3/7/2007 12:39:17 PM
	of 946

From a BusinessWire issued Zack's PR ... More Bullish Than the Street on CTIC Cell Therapeutics, Inc. (Nasdaq: CTIC) develops, acquires and commercializes novel treatments for cancer. Two pipeline products, Xyotax and Pixantrone, account for the late-stage oncology focus. In September, 2006, CTIC entered into a partnership agreement with Novartis for Xyotax and Pixantrone. We are optimistic about Cell Therapeutics future, and believe the shares are attractive at current levels. In our view, the Street is overly pessimistic on the development programs for Xyotax and Pixantrone. We continue to rate the stock a Buy, with a price target of $3.50. At the current price, Cell Therapeutics commands a market capitalization of approximately $207 million. Based on our 2008 revenue estimate of approximately $89.5 million, this equates to a 2008 Price / Sales ratio of only 2.3x. This is an enormous discount to the overall biotechnology peer group price/sales average of 10x 2008 revenues. See the latest posts to the Analyst Blog by visiting at.zacks.com About Zacks Equity Research Zacks Equity Research provides the best of quantitative and qualitative analysis to help investors know what stocks to buy and which to sell for the long-term. Continuous coverage is provided for a universe of 1,150 publicly traded stocks. Our analysts are organized by industry which gives them keen insights to developments that affect company profits and stock performance. Recommendations and target prices are six-month time horizons. Zacks "Profit from the Pros" e-mail newsletter provides highlights of the latest analysis from Zacks Equity Research. Subscribe to this free newsletter today by visiting at.zacks.com. ...

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next